The PainChek (ASX:PCK) share price is rising on its latest announcement

Shares in PainChek Ltd are gaining today after the company has received regulatory clearances for its app, PainChek Infant.

| More on:
A boy looks up and points his fingers to the sky in celebration pose.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in PainChek Ltd (ASX: PCK) are gaining today after news the company has received regulatory clearances for its app, PainChek Infant. At the time of writing, the PainChek share price is up 6.15%, with shares in the company swapping hands for 6.9 cents apiece.

As a result of the clearances, PainChek can market its pain sensing app for babies in Australia, Europe, the United Kingdom, Canada, Singapore, and New Zealand.

PainChek also announced its successful Infant Face-Only study is being peer-reviewed for publication. The study determined the app could successfully analyse a baby's facial expressions and evaluate if they're in pain.

Let's take a closer look at the latest news from Painchek.  

PainChek Infant

Painchek has announced that it's received a number of regulatory approvals needed market its PainChek Infant app.

The company now plans to launch its infant app in a number of countries. It will focus particularly on the hospital and home care markets.

PainChek says that its app can help healthcare professionals, parents, and carers to evaluate if a non-verbal child is in pain. Additionally, the app will help gauge how much pain the child is in.

According to PainChek, there are around 400 million pre-verbal children globally. Moreover, one quarter is born to first-time parents. Furthermore, PainChek stated this gives it a large market entry point.

The company also said that, while clinicians have access to paper-based pain measuring tools for infants, they are rarely used. Additionally, it claimed that high levels of exposure to pained infants can sometimes lead to medical professionals dismissing babies' pain signals.

PainChek plans to continue expanding its app's abilities. Currently, it is working to broaden the age range of children whose pain can be assessed. It will do so by conducting further research and clinical studies. It is also currently conducting a study at Melbourne's Royal Children's Hospital.

PainChek already has an app available that uses facial expressions to sense pain in non-verbal adults.

Commentary from management

PainChek's CEO Philip Daffas commented on the PainChek Infant app's approval, saying:

We're delighted to achieve this regulatory milestone ahead of schedule and continue to expand PainChek's global markets. The PainChek Infant App is unique in that it completes a microfacial analysis through a 3 second video assessment and provides the carer with an instant result in relation to the infant's pain severity level…

Having established the initial PainChek Adult App and the business model in aged care, this broad portfolio of offerings provides the foundation for our global market entry into the larger home care and the hospital markets.

PainChek share price snapshot

The PainChek share price needs the good news as it battles a tough 2021 on the ASX.

Currently, the PainChek share price is down 12.5% year to date. It's also fallen 56% since this time last year.

The company has a market capitalisation of around $73 million, with approximately 1.1 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Earnings Results

Nanosonics share price crashes 14% on first-half profit crunch

Investors haven't responded positively to the release of the company's half-year results.

Read more »

Three excited business people cheer around a laptop in the office
Healthcare Shares

Here's why ResMed shares can jump a further 20%

Investors have done very well from this stock recently. The good news is that analysts expect the trend to continue.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

Sonic Healthcare shares hit 52-week low as analysts take a scalpel to targets

Analysts have sharpened the knives after the latest blood-sucking half year at Sonic Healthcare.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »